Bone is the most commonly seen metastatic site in all the metastatic breast cancer (MBC). Treatment includes systemic treatment according to different molecular subtypes and specified treatment of the bone. Bisphosphonate and denosumab are the only two drugs approved to use in bone metastatic site. The optimal dosing schedule and duration of the drugs are still under research. New drugs and therapies including curcuminoids, sunitinib and nano particles are potentially available in the near future.
Keywords: Metastatic breast cancer (MBC); bisphosphonate; bone metastasis (BM); denosumab.